INDIANAPOLIS, Oct. 17, 2016 /PRNewswire/ -- With the
global prevalence of new cancer cases expected to rise by 70
percent during the next two decades, representatives from
government, academic, pharmaceutical and diagnostic companies are
pooling their knowledge to accelerate treatments to
patients.1 Today, Eli Lilly and Company (NYSE: LLY)
announced it will contribute cancer research data to the National
Cancer Institute's Blood Profiling Atlas, an open access liquid
biopsy database being created in response to Vice President
Joe Biden's call to action and in
alignment with the goals of the Cancer Moonshot initiative. The
database is an effort to reduce the development time of effective
and safe blood profiling diagnostic technologies.
"We are honored to be a part of this unique partnership," said
Andrew Schade, M.D., Ph.D., a
distinguished medical fellow in Lilly's clinical diagnostics
laboratory. "Liquid biopsies are going to be critical in the future
to both identify specific patients for targeted therapies and to
follow their treatment to better determine response to therapy. We
hope knowledge gained from our research efforts in this area will
help to accelerate the development of safe and effective blood
profiling diagnostic technologies that help people with
cancer."
In support of this overarching mission, Lilly is studying
approaches for the profiling of exosomes for mRNA and non-coding
RNA expression and will share sample preparation methods,
next-generation quantitative PCR-based methods, and next generation
sequencing-based methods along with data related to disease
characterization through gene expression analysis.
"Our scientists are dedicated to discovering and developing new
cancer treatments to help people living with this disease," said
Jan Lundberg, Ph.D., executive vice
president of science and technology and president of Lilly Research
Laboratories. "In addition to our own research, external
partnerships are paramount, and we look forward to collaborating
with other experts as part of the Cancer Moonshot initiative."
The Blood Profiling Atlas is part of the Cancer Moonshot
initiative, which was established to improve the way research is
conducted and expedite the delivery of medicines to patients.
Allowing approved researchers access to raw unprocessed datasets in
a scalable and reproducible manner, the open database will feature
the following data: raw data sets from circulating tumor cells,
circulating tumor DNA, and exosome assays, as well as relevant
clinical data, sample preparation, and handling protocols from 12
different studies. The Blood Profiling Atlas pilot will be curated
by a partnership between the University of
Chicago and Seven Bridges, a biomedical data analysis
company. For more information about the Blood Profiling Atlas,
please click here.
About Lilly Oncology
For more than 50 years, Lilly has
been dedicated to delivering life-changing medicines and support to
people living with cancer and those who care for them. Lilly is
determined to build on this heritage and continue making life
better for all those affected by cancer around the world. To learn
more about Lilly's commitment to people with cancer, please visit
www.LillyOncology.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels. (P-LLY)
Lilly Forward-Looking Statement
This press release
contains "forward-looking statements" (as that term is defined
in the United States Private Securities Litigation Reform
Act of 1995) regarding Lilly's efforts to the National Cancer
Institute's Blood Profiling Atlas, and reflects Lilly's current
beliefs. However, there are substantial risks and uncertainties in
the process of drug research, development and commercialization.
Among other risks, there can be no guarantee that these
investigational combination regimens will receive regulatory
approval, or, if approved, will achieve intended benefits or become
commercially successful. For further discussion of these and other
risks and uncertainties that could cause actual results to differ
materially from Lilly's expectations, please see the company's
latest Forms 10-K and 10-Q filed with the U.S. Securities and
Exchange Commission. Except as required by law, Lilly undertakes no
duty to update forward-looking statements for events occurring
after the date of this release.
1 Cancer. World Health Organization.
http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed
October 2016.
Refer to: Media – Amy
Sousa; sousa_amy_e@lilly.com; (317) 997-1481
Logo- http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-partners-with-the-national-cancer-institute-to-accelerate-cancer-research-through-new-program-under-cancer-moonshot-initiative-300345866.html
SOURCE Eli Lilly and Company